Yazar "Yurt M." seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • [ X ]
    Öğe
    Hereditary thrombophilic risk factors in patients with deep venous thrombosis
    (2007) Altintaş A.; Çil T.; Kaplan M.A.; Yurt M.; Batun S.
    The prevalence of hereditary risk factors for deep venous thrombosis (DVT) varies greatly in different parts of the world. Factor V Leiden (FVL) and prothrombin G 20210A (FT G20210A) are the most common genetic defects leading to venous thrombosis. The aim of this study was to investigate the frequency of FVL and PT G20210A mutations in adult patient with DVT in our region. Between September 2001 and August 2006, 52 patients with documented venous thrombosis were investigated in our center for the presence of FVL and PT G20210A mutations. Fourteen of 52 patients with thrombosis (%26.9) were detected to have a FVL mutation. The PT G20210A mutation was detected in 6 (%11) of the 52 patients. Our findings reveal that FVL and PT G20210A mutations are significantly higher in patients with DVT than in the healty population in the southeast of Turkey.
  • [ X ]
    Öğe
    Quantitative analysis of t(8,21) and inv(16) via RT-PCR in patients with acute myeloid leukemia
    (2005) Ayyildiz O.; Kalkanli S.; Batun S.; Işikdo?an A.; Söker M.; Yurt M.; Müftüo?lu E.
    It has been showed that there is a relation between chromosomal abnormality and prognosis in acute myeloid leukemia (AML). There are many chromosomal abnormalities in AML patients and it is known that t(8;21) and inv(16) are good prognostic abnormalities. Recently the treatment has been planned according to these abnormalities. We investigated t(8,21) and inv(16) abnormalities by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in 19 patients with AML. Morever conventional cytogenetic method was applied for all patients. Of whom 9 were men and 10 women. Age of avarage was 19 to 58 years. FAB morphologic classification follows as; 5 AML-M1, 8 AML-M2, 5 AML-M4, 1 AML-M5. Complete remission was obtained in eighteen patients with first induction regimen, whereas in one patient after second induction. t(8;21) has been found in 1 patient with cytogenetic method and confirmed with RT-PCR. In this study, we aim to search t(8;21) and inv(16) abnormalities in AML cases.
  • [ X ]
    Öğe
    The Role of FLT3-ITD and CCAAT-Enhancer-Binding Protein ? Mutations on Prognosis of Acute Lymphoblastic Leukaemia in Turkish Patients
    (University of the West Indies, 2022) Uluca U.; Söker M.; Ayyıldız M.O.; Yurt M.; Şen V.; Yel S.; Güneş A.
    Background: Acute lymphoblastic leukaemia (ALL) is the most common malignancy in childhood. Although some prognostic factors have been defined to date, the estimation of prognosis is currently not perfect. Previous studies had shown an association of FLT3 with poor prognosis and CCAAT-enhancer-binding protein ? (CEBPA) mutation with the development of acute myeloid leukaemia (AML). Here, we aimed to evaluate the prognostic value of FLT3-ITD and CEBPA mutations in ALL. Methods: Sixty-one patients with ALL were included in the study. The patients were divided into three risk groups according to BFM risk classification. All of the patients were examined for FLT3-ITD mutations and 45 of them for CEBPA mutations. Mutation positive and negative patients were compared in terms of their risk groups, translocations and cell lineage. The clinical courses of the patients were appraised. Results: FLT3-ITD mutation was detected in 3 of the 61 patients, and CEBPA mutations were detected in 11 of the 45 patients. The incidence of established prognostic indicators including BFM risk classification, t(9; 22); BCR-ABL, t(1; 19); E2A-PBX1, t(12; 21); TEL-AML1, t(4; 11); MLL-AF4 were similar between FLT3-ITD and CEBPA positive and negative patients. A patient with an FLT3-ITD mutation was very susceptible to pancytopenia after maintenance treatment and two other patients with FLT3-ITD mutations were more prone to febrile neutropenia. Conclusion: Our results suggested that CEBPA or FLT3-ITD mutations might not be related to ALL prognosis in the sampled Turkish patients. However, FLT3-ITD mutation might have an influence on the response of bone marrow to chemotherapy. © West Indian Medical Journal 2022. This is an article published in open access under a Creative Commons Attribution International licence (CC BY). For more information, please visit https://creativecommons.org/licenses/by/4.0/deed.en_US